塞德斯医疗 CLDX 深 沪
已收盘 08-01 16:00:00 美东时间
22.19
+0.210
+0.96%
华盛通- 最 高22.3925
- 今 开21.81
- 成交量 76.81万股
- 最 低 21.685
- 昨 收 21.98
- 总市值 14.73亿
- 52周最高 47.00
- 市盈率 静 --
- 换手率 1.16%
- 52周最低 14.40
- 委 比 83.14%
- 总股本 6639.42万
- 历史最高 582.60
- 量 比 0.83
- 振 幅 3.22%
- 历史最低 1.50
- 每 手 1
- 风险率 6.66%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
Calidi Biotherapeutics announced a 1-for-12 reverse stock split, effective August 5, 2025, to optimize market dynamics and broaden investor appeal. Post-split shares will trade under the same symbol "CLDI" with a new CUSIP number. Shareholders will receive one share for every twelve pre-split shares, with fractional shares rounded up. The split does not affect par value, authorized shares, or preferred stock. The company expects this move to enha...
07-25 20:45
Calidi Biotherapeutics Announces Shareholder Letter from CEO
Calidi Biotherapeutics Inc. (CLDI) reported significant progress in 2025, including leadership changes, cost reductions, and advancements in its R&D pipeline. The company highlighted the rapid development of its RedTail platform, which delivers genetic medicines to metastatic cancer sites using an engineered enveloped virus. Recent preclinical data at AACR and ASCO meetings demonstrated RedTail's tumor-selective targeting and immune modulation ca...
06-27 12:00
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
Celldex Therapeutics announced that barzolvolimab significantly improved angioedema in patients with chronic spontaneous urticaria (CSU) over 52 weeks in a Phase 2 trial. The study showed that 77% of patients with baseline angioedema were angioedema-free at Week 52. Barzolvolimab also demonstrated a favorable safety profile and clinically meaningful reductions in angioedema activity, supporting its potential as a transformative treatment for CSU....
06-14 14:48
Unusual Machines Acquires Rotor Lab To Strengthen Drone Supply Chain
Unusual Machines boosts drone ambitions with Rotor Lab acquisition, while dropping Aloft deal over strategic misalignment.
06-13 23:56
Forecasting The Future: 8 Analyst Projections For Celldex Therapeutics
Providing a diverse range of perspectives from bullish to bearish, 8 analysts h...
06-13 20:01
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
Celldex announced that data from its Phase 2 study of barzolvolimab in chronic spontaneous urticaria will be presented at the EAACI Congress 2025 in Glasgow. A webcast on June 12 at 6:00 pm ET will discuss the data, which include 76-week efficacy and tolerability, as well as 52-week angioedema results. Presenters include Celldex representatives and Martin Metz, MD. Abstracts will be available on June 12 at 6:01 pm ET.
06-10 20:01
Celldex Approves Equity Plan Amendment and Elects New Director
The latest announcement is out from Celldex ( ($CLDX) ). On June 5, 2025, Celld...
06-06 20:29
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
Celldex Therapeutics, Inc. announces the election of Denice M. Torres to its Board of Directors. Torres, CEO of The Ignited Company and former senior leader at Johnson & Johnson, brings extensive experience in pharma and consumer healthcare. She expressed excitement about contributing to Celldex's growth, particularly with its barzolvolimab. Celldex CEO Anthony Marucci highlighted Torres' strategic and operational expertise, which will support th...
06-06 12:01
